Loading…
Loading…
SNN launches the LYNX COBLATION Laryngeal Wand, combining precise dissection, rapid debulking and hemostasis for airway procedures.
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication by expert clinicians of new consensus-based guidance - developed by them for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany and has been published in the internationally recognised journal of surgery Die Chirurgie. The new German consensus was supported by Smith+Nephew, a pioneer in sNPWT and manufacturer of the PICO™7 sNPWT system.
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication of new consensus-based guidance - developed independently by expert clinicians for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany. Published in internationally recognised journal of surgery Die Chirurgie, the new German consensus was supported by Smith+Nephew, a pioneer in sNPWT and manufacturer of the PICO™7 sNPWT system.
Smith & Nephew continues to demonstrate solid business recovery, with robust revenue, profit, and free cash flow growth across all divisions. SNN's 2026 outlook targets 6% underlying revenue growth, 8% organic trading profit growth, and $800 million in free cash flow, with a new $500 million share buyback announced. Completion of the 12-point plan delivered mixed results: revenue growth targets were met, but trading margin fell short, prompting a new 'RISE' strategy with 2028 financial targets.
Smith & Nephew plc (SNN) Shareholder/Analyst Call Transcript
Smith & Nephew PLC (LSE:SN) efforts to expand its surgical robotics platform and strengthen its orthopaedics pipeline received a vote of confidence from surgeons at a recent investor event, according to analysts at JPMorgan. Analyst Veronika Dubajova said discussions at the medical technology group's Expert Surgeon Insights event in London left her incrementally more positive on the prospects for CORI, Smith & Nephew's robotic-assisted surgery platform.
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, marking an important milestone in the clinical introduction of its latest handheld robotics technology. CORI XT Handheld Robotic Platform is designed to be the single handheld robotics platform for all orthopaedic needs - partial to revision knee, hip*, and anatomic and reverse shoulders - with a footprint tailored to the unique needs of hospitals and ambulatory surgical suites settings.
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the US launch of next generation LEAF ♢ Patient Monitoring System, a data-driven pressure injury prevention platform designed to help health care providers tackle the growing burden of hospital-acquired pressure injuries (HAPIs) by strengthening protocols and outcomes. The LEAF System uses a wearable sensor to monitor patient mobility and provide real-time turn status updates, helping to improve workflow efficiency, turn quality, and protocol adherence.1-3
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for SNN and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.